Category: HSV
A recently completed international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment to suppress herpes simplex virus-2 (HSV-2), which is the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2.
A topical microbicide that silences two genes can safely protect against genital herpes infection for as long as one week.
A study led by Dr. Herbert Kaufman, Boyd Professor of Ophthalmology at Louisiana State University Health Sciences Center in New Orleans, published in the January issue of Investigative Ophthalmology & Visual Science, found that 98% of the participants who are healthy individuals with no evidence of any symptoms did in fact shed herpes simplex virus type I (HSV-1) DNA in their tears and saliva at least once during the course of the 30-day study. The study was undertaken to assess the frequency of shedding of HSV-1 DNA in tears and saliva of asymptomatic individuals.
A new study provides evidence that a herpes vaccine developed by a Harvard Medical School researcher is a strong candidate for testing in humans. The study, published online Dec. 14 in the Journal of Virology, compared three different experimental vaccines for herpes simplex virus 2 (HSV-2), the virus that causes most cases of genital herpes.
For over 30 years, physicians have assumed that any expectant mother with genital herpes lesions at delivery must deliver her baby by Caesarian section to minimize chances of transmission of the disease to the infant, although there was no clinical or research information supporting that practice. A study by University of Washington physicians confirms that Caesarian section is indeed the way to go to prevent transmission of HSV (herpes simplex virus).